STANLEY L HAZEN
Osteopathic Medicine in Cleveland, OH

2011028, Nov 24, 2011

Jul 14, 2011

13/183165

Stanley L. Hazen - Pepper Pike OH, US
Renliang Zhang - Cleveland OH, US

THE CLEVELAND CLINIC FOUNDATION - Cleveland OH

G01N 33/573, C12Q 1/28

435 74, 435 28, 435 792

Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from healthy controls. Such comparison characterizes the test subject's risk of developing CVD.

2013028, Oct 24, 2013

Nov 10, 2011

13/884577

Stanley L. Hazen - Pepper Pike OH, US

THE CLEVELAND CLINIC FOUNDATION - Cleveland OH

G01N 33/92

435 611, 436501, 435 792

The present disclosure provides methods and markers for characterizing a subject's, particularly a human subject's, risk of having cardiovascular disease. The present disclosure also provides methods of characterizing a subject's risk of developing cardiovascular disease. In another embodiment, the present disclosure provides methods for characterizing a subject's risk of experiencing a complication of cardiovascular disease or major adverse cardiac event within 3 months, 6 months, 1 year, 3 years, 5 years, or 10 years. In another embodiment, the present disclosure provides a method for determining whether a subject presenting with chest pain is at risk near term of experiencing a heart attack or other major adverse cardiac event. The present methods are especially useful for identifying those subjects who are in need of highly aggressive CVD therapies as well as those subjects who require no therapies targeted at inhibiting or preventing CVD or complications of CVD.

7378396, May 27, 2008

Aug 5, 2005

11/198005

Stanley L. Hazen - Pepper Pike OH, US
Marc S. Penn - Beachwood OH, US

The Cleveland Clinic Foundation - Cleveland OH

A61K 38/07, A61K 38/08, A61K 38/10, A61K 38/16

514 14, 514 13, 514 15, 514 16, 514 17, 514 18, 530326, 530327, 530328, 530329, 530330

The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoA1 peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD. The method comprises incubating one or more test agents and MPO with a molecule comprising the MPO binding site of apoA-1 under conditions which permit binding of MPO to the MPO binding site and determining whether one or more of the agents inhibit such binding.

8309320, Nov 13, 2012

Dec 1, 2009

12/628841

Claudia R. Morris - Oakland CA, US
Stanley L. Hazen - Cleveland OH, US

Children's Hospital & Research Center at Oakland - Oakland CA
The Cleveland Clinic Foundation - Cleveland OH

C12Q 1/34, G01N 33/50, G01N 33/00, C12P 13/10, C12N 9/14, C12N 9/78, G01N 31/00, A61K 38/00

435 18, 435114, 435195, 435227, 436 16, 436 68, 436 86, 436116, 514 157

The invention features methods and compositions for diagnosis, including prognosis, of conditions associated with decreased arginine bioavailability (which can result from dysregulated arginine metabolism, e. g. , due to increased arginase activity) by assessing in a sample from a subject the ratio of arginine to one or more, usually two or more, modulators of arginine bioavailability. In one embodiment, the ratio of arginine to (ornithine+citrulline) is assessed to aid in diagnosis.

2006021, Sep 21, 2006

Feb 13, 2006

11/352930

Stanley Hazen - Pepper Pike OH, US
Suzy Comhair - Concord Township OH, US

C12Q 1/26

435025000

Provided herein are diagnostic and prognostic methods, diagnostic and prognositic markers, and methods for evaluating anti-inflammatory agents or drugs in subjects with asthma and/or an analogous disease associated with high oxidative and nitrative stress at the disease site. In certain embodiments, the methods comprise a step of assaying for decreased levels of superoxide dismutase activity in the blood, serum, or plasma of the subject. In certain embodiments, the methods comprise a step of assaying for elevated levels of one or more oxidatively-modified SOD isoforms or species in the blood, serum or plasma of the subject. Also provided are diagnostic kits for use in the present invention. In certain embodiments, such kits comprise at least one binding reagent that specifically binds to at least one oxidatively-modified SOD species.

2011030, Dec 15, 2011

Jun 15, 2011

13/160941

Stanley L. Hazen - Pepper Pike OH, US
Joseph DiDonato - Westlake OH, US

THE CLEVELAND CLINIC FOUNDATION - Cleveland OH

A61K 39/395, G01N 33/48, A61K 31/711, A61P 35/00, A61K 38/02, A61K 31/7105

4241521, 514 74, 514 44 R, 436 71

The present invention provides methods for treating cancer in a subject, as well as related compositions and kits that employ a therapeutic agent, or a nucleic acid sequence encoding a therapeutic agent, selected from apolipoprotein A-1 (ApoA1) or biologically active fragment, an ApoA1 mimetic, an agent that increases expression of ApoA1, or a binding agent specific for oxidized ApoA1. In certain embodiments, the ApoA1 or ApoA1 mimetic is at least partially oxidation resistant.

2013031, Nov 28, 2013

May 14, 2013

13/893425

Satish Kalhan - Pepper Pike OH, US
Stanley Hazen - Pepper Pike OH, US

THE CLEVELAND CLINIC FOUNDATION - Cleveland OH

G01N 33/483

4241331, 514171, 250282

The present invention provides methods, kits, and compositions related to testing a sample for the level of a biomarker related to asthma, wherein the biomarker is selected from: taurine, maltose, maltotriose, adenosine 5′-monophosphate, phosphoethanolamine, glycerophosphorylcholine, arachidonate, heptanoate, pelargonate, and nicotinamide. In certain embodiments, the level of the biomarker is used to identify therapy effective for treating asthma. In other embodiments, the level of the biomarker is used to identify the presence, severity, or risk of exacerbation of asthma. In further embodiments, the level of the biomarker is used to monitor the response to on-going therapy (e.g., adjust the dosage of the asthma therapy).

2009020, Aug 20, 2009

Mar 14, 2008

12/048471

Stanley L. Hazen - Pepper Pike OH, US
Stephen James Nicholls - Cleveland Heights OH, US

The Cleveland Clinic Foundation - Cleveland OH

C12Q 1/44

435 19

Provided herein are methods for assessing the risk a subject or patient without significant evidence of cardiovascular disease has of experiencing a major adverse cardiac event or requiring revascularization near term. Also provided are methods of determining whether a subject who has experienced a major adverse cardiac event is at risk of experiencing a recurrent major adverse cardiac event near term. The present methods comprise determining the levels of paraoxonase 1 enzymatic activity in the blood, serum, plasma, or any combination of said bodily fluids in the subject.

8143224, Mar 27, 2012

Oct 23, 2008

12/256822

Jonathan D. Smith - Shaker Heights OH, US
Stanley L. Hazen - Pepper Pike OH, US

The Cleveland Clinic Foundation - Cleveland OH

A61K 38/10, C07K 14/00

514 212, 530324, 530350, 435375

A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation.